BioSpace News Archive

According to Nova one advisor, the global Overactive Bladder Treatment (OAB) market size is expected to hit around USD 8.2 billion by 2030 from valued at USD 3.9 billion in 2022 and growing at a CAGR of 4.6% from 2022 to 2030.

Latest Study on “Transthyretin Amyloidosis Treatment Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2022-2030”.

According to Nova one advisor, the global Biologics market size is expected to hit around USD 719.94 billion by 2030 from valued at USD 366.50 billion in 2021 and growing at a CAGR of 7.15% from 2022 to 2030.

According to Nova one advisor, the global Monkeypox Vaccine And Treatment market size is expected to hit around USD 214.79 million by 2030 from valued at USD 85.43 million in 2022 and growing at a CAGR of 10.26% from 2022 to 2030.

According to Nova one advisor, the global Non-opioid Pain Treatment market size is expected to hit around USD 78.01 billion by 2030 from valued at USD 38.94 billion in 2021 and growing at a CAGR of 8.60% from 2022 to 2030.

CSL Seqirus announced that the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, selected CSL Seqirus to deliver an H5N8 A/Astrakhan virus vaccine candidate for assessment in a Phase 2 clinical study that is anticipated to begin in Q2 2023.

RealTime Software Solutions, LLC has partnered with Aspen Insights to integrate a best-in-class EMR/EHR patient identification technology into RealTime’s world-class Clinical Trial Management System (CTMS).

Gemina Laboratories Ltd. is pleased to announce that it has entered into agreement with International Point of Care, Inc, for the manufacturing of its Legio XTM COVID-19 Rapid Antigen Test.

Octapharma announced today the results from the ProDERM study on the efficacy and safety of octagam® 10% [Immune Globulin Intravenous (Human)], in adult dermatomyositis (DM) patients have been published in the New England Journal of Medicine (Aggarwal R et al. “Efficacy and safety of intravenous immunoglobulin in dermatomyositis”).

Parallel ENT & Allergy Partners has added a second state to its roster of high-quality, innovative ENT and allergy partners with the addition of Grand Rapids ENT.